Difference of gut microbiota between patients with negative and positive HBeAg in chronic hepatitis B and the effect of tenofovir alafenamide on intestinal flora
BackgroundSevere liver diseases, such as liver fibrosis, cirrhosis, and liver cancer, are mainly caused by hepatitis B virus (HBV). This study investigated the differences between gut microbiota in HBeAg-positive and negative groups of patients with chronic hepatitis B (CHB) and investigated the eff...
Main Authors: | Jianfei Long, Jingru Gong, Han Zhu, Xiaolin Liu, Ling Li, Bicui Chen, Hongyan Ren, Chao Liu, Huiping Lu, Jiming Zhang, Bin Wang |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2023-09-01
|
Series: | Frontiers in Microbiology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fmicb.2023.1232180/full |
Similar Items
-
Corrigendum: Difference of gut microbiota between patients with negative and positive HBeAg in chronic hepatitis B and the effect of tenofovir alafenamide on intestinal flora
by: Jianfei Long, et al.
Published: (2023-11-01) -
Long-Term HBsAg Titer Kinetics with Entecavir/Tenofovir: Implications for Predicting Functional Cure and Low Levels
by: Soon Kyu Lee, et al.
Published: (2024-02-01) -
Switching from entecavir to tenofovir disoproxil fumarate for HBeAg-positive chronic hepatitis B patients: a phase 4, prospective study
by: Fumitaka Suzuki, et al.
Published: (2021-12-01) -
Suboptimal Response to Tenofovir Alafenamide in Two Patients With HBeAg-Positive Hepatitis B: A Case Report
by: Ruochan Chen, et al.
Published: (2021-07-01) -
End-of-treatment anti-HBs levels and HBeAg status identify durability of HBsAg loss after PEG-IFN discontinuation
by: Yifei Guo, et al.
Published: (2023-02-01)